Faron, etusivu

Tiedotteet ja julkaisut

Faron Pharmaceuticals julkistaa tiedotteensa englannin kielellä.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Shareholder announcement Regulatory

The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus

Regulatory

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Shareholder announcement Regulatory

Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway

Regulatory

Update to Faron’s Financial Calendar and date of the Annual General Meeting in 2026

Regulatory

Correction: Faron Pharmaceuticals Ltd’s Annual Report 2025 published

Regulatory

Faron Pharmaceuticals Ltd’s Annual Report 2025 published

Regulatory

Faron’s Financial Statements Release 1 January to 31 December 2025

Regulatory

Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting

Regulatory

Faron and City of Hope in process of developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS

Next
Siirry takaisin sivun alkuun